A Study To Evaluate The Safety And Tolerability Of PF-03882845 In Patients With Type 2 Diabetic Nephropathy

Stopped early · Phase 1 · Has a placebo group

Conditions studied: Type 2 Diabetic Nephropathy

In brief

PF-03882845 is a compound proposed for treatment of type 2 diabetic nephropathy. The primary purpose of this trial is to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of multiple doses of PF-03882845 in this population.

Key facts

Study ID

NCT01488877

Run by

Pfizer

People needed

6

Starts

2012-01-01

Expected to finish

2012-07-01

Last updated by the study team

2013-10-29

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and/or Females between 18-65 years, inclusive.
• Body mass index of 18.5 to 45.4 kg/m2 at screening, inclusive. body weight equals or greater than 110 lb.
• Have type 2 diabetes mellitus.
• On stable dose of anti-diabetic and anti-hypertensive medication prior to screening.

You may not qualify if…

• Recent evidence or medical history of unstable concurrent disease.
• Cardiovascular event within 3 months prior to screening.
• History of renal transplant.
• History of hospitalization for acute kidney injury or acute kidney dialysis within 6 months prior to screening.

Where it is running

• Pfizer Investigational Site — Chula Vista, California, United States
• Pfizer Investigational Site — San Diego, California, United States
• Pfizer Investigational Site — DeLand, Florida, United States
• Pfizer Investigational Site — Miami, Florida, United States
• Pfizer Investigational Site — Kalamazoo, Michigan, United States
• Pfizer Investigational Site — New York, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.